Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2011139917) MODULATION OF TRANSTHYRETIN EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2011/139917 International Application No.: PCT/US2011/034661
Publication Date: 10.11.2011 International Filing Date: 29.04.2011
IPC:
C12N 15/11 (2006.01) ,C07H 21/04 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04
with deoxyribosyl as saccharide radical
Applicants:
MONIA, Brett, P. [US/US]; US (UsOnly)
FREIER, Susan, M. [US/US]; US (UsOnly)
SIWKOWSKI, Andrew, M. [US/US]; US (UsOnly)
ISIS PHARMACEUTICALS, INC. [US/US]; 2855 Gazelle Court Carlsbad, CA 92010, US (AllExceptUS)
Inventors:
MONIA, Brett, P.; US
FREIER, Susan, M.; US
SIWKOWSKI, Andrew, M.; US
Agent:
MALLON, Joseph; Knobbe, Martens, Olson, and Bear LLP 2040 Main Street 14th Floor Irvine, California 92614, US
Priority Data:
61/329,53829.04.2010US
61/405,16320.10.2010US
Title (EN) MODULATION OF TRANSTHYRETIN EXPRESSION
(FR) MODULATION DE L'EXPRESSION DE LA TRANSTHYRÉTINE
Abstract:
(EN) Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
(FR) L'invention concerne des procédés, des composés et des compositions permettant de réduire l'expression d'ARNm et de protéine de la transthyrétine chez un animal. Ces procédés, composés et compositions sont utiles pour traiter, prévenir, retarder ou améliorer l'amyloïdose de la transthyrétine, ou un symptôme de celle-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)